Skip to main content
. 2020 Jul 2;22(10):1425–1438. doi: 10.1093/neuonc/noaa154

Fig. 1.

Fig. 1

New frontiers in brain tumor immunotherapy. (A) Identifying patients with tumor genomic features that correlate with increased response to checkpoint blockade immunotherapy. (B) Administration of checkpoint blockade immunotherapy prior to surgery in the neoadjuvant setting. (C) Generating of therapeutic personalized cancer vaccines targeting GBM neoantigens. (D) Generation of CAR T cells from autologous patient peripheral blood mononuclear cells.